A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

346

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis

Interventions

DRUG: Povorcitinib
DRUG: Placebo

Sponsor

Incyte Corporation